Decrease of urinary nerve growth factor but not brain-derived neurotrophic factor in patients with interstitial cystitis/bladder pain syndrome treated with hyaluronic acid

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Jiang, Yuan Hong ^a   Liu, Hsin Tzu ^a   Kuo, Hann Chorng ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CREATININE; HYALURONIC ACID; NERVE GROWTH FACTOR;

ADOLESCENT; ADULT; ANALYTICAL PARAMETERS; ARTICLE; BLADDER CAPACITY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; CYSTALGIA; DRUG EFFICACY; FEMALE; GLOBAL RESPONSE ASSESSMENT; HUMAN; INTERSTITIAL CYSTITIS; MALE; NOCTURIA; PAIN ASSESSMENT; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN URINE LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; URINALYSIS; VISUAL ANALOG SCALE; CASE CONTROL STUDY; CLINICAL TRIAL; CYSTITIS, INTERSTITIAL; INTRAVESICAL DRUG ADMINISTRATION; MIDDLE AGED; URINE; YOUNG ADULT;

ADMINISTRATION, INTRAVESICAL; ADOLESCENT; ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; CREATININE; CYSTITIS, INTERSTITIAL; FEMALE; HUMANS; HYALURONIC ACID; MALE; MIDDLE AGED; NERVE GROWTH FACTOR; YOUNG ADULT;

EID: 84897486933     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091609     Document Type: Article

References (33)

1. Homma Y, Ueda T, Tomoe H, Lin AT, Kuo HC, et al. (2009) Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome. Int J Urol 16: 5972615.
2. Nickel JC (2004) Interstitial cystitis: a chronic pelvic pain syndrome. Med Clin North Am 88: 4672481, xii.
3. Shie JH, Kuo HC (2011) Higher levels of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis/painful bladder syndrome. BJU Int 108: E1362 141.
4. Parsons CL (2007) The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis. Urology 69: 9216.
5. Kuo H-C (2012) Novel treatments of interstitial cystitis/bladder pain syndrome based on pathophysiology. Clinical Investigation 2: 108521100.
6. Hurst RE, Rhodes SW, Adamson PB, Parsons CL, Roy JB (1987) Functional and structural characteristics of the glycosaminoglycans of the bladder luminal surface. J Urol 138: 4332437.
7. Hurst RE, Roy JB, Min KW, Veltri RW, Marley G, et al. (1996) A deficit of chondroitin sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis. Urology 48: 8172821.
8. Parsons CL, Lilly JD, Stein P (1991) Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol 145: 7322735.
9. Lokeshwar VB, Selzer MG, Unwala DJ, Estrella V, Gomez MF, et al. (2006) Uronate peaks and urinary hyaluronic acid levels correlate with interstitial cystitis severity. J Urol 176: 100121007.
10. Morales A, Emerson L, Nickel JC, Lundie M (1996) Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol 156: 45248.
11. Porru D, Campus G, Tudino D, Valdes E, Vespa A, et al. (1997) Results of treatment of refractory interstitial cystitis with intravesical hyaluronic acid. Urol Int 59: 26229.
12. Kallestrup EB, Jorgensen SS, Nordling J, Hald T (2005) Treatment of interstitial cystitis with Cystistat: a hyaluronic acid product. Scand J Urol Nephrol 39: 1432147.
13. Daha LK, Riedl CR, Lazar D, Hohlbrugger G, Pfluger H (2005) Do cystometric findings predict the results of intravesical hyaluronic acid in women with interstitial cystitis? Eur Urol 47: 3932397; discussion 397.
14. Riedl CR, Engelhardt PF, Daha KL, Morakis N, Pfluger H (2008) Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 19: 7172721.
15. Daha LK, Riedl CR, Lazar D, Simak R, Pfluger H (2008) Effect of intravesical glycosaminoglycan substitution therapy on bladder pain syndrome/interstitial cystitis, bladder capacity and potassium sensitivity. Scand J Urol Nephrol 42: 3692372.
16. Engelhardt PF, Morakis N, Daha LK, Esterbauer B, Riedl CR (2011) Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. Int Urogynecol J 22: 4012405.
17. Frias B, Lopes T, Pinto R, Cruz F, Cruz CD (2011) Neurotrophins in the lower urinary tract: becoming of age. Curr Neuropharmacol 9: 5532558.
18. Ochodnicky P, Cruz CD, Yoshimura N, Michel MC (2011) Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol Urodyn 30: 122721241.
19. Ochodnicky P, Cruz CD, Yoshimura N, Cruz F (2012) Neurotrophins as regulators of urinary bladder function. Nat Rev Urol 9: 6282637.
20. Antunes-Lopes T, Pinto R, Barros SC, Botelho F, Silva CM, et al. (2013) Urinary neurotrophic factors in healthy individuals and patients with overactive bladder. J Urol 189: 3592365.
21. Tyagi P, Killinger K, Tyagi V, Nirmal J, Chancellor M, et al. (2012) Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis. J Urol 187: 224322248.
22. Liu HT, Kuo HC (2012) Increased urine and serum nerve growth factor levels in interstitial cystitis suggest chronic inflammation is involved in the pathogenesis of disease. PLoS One 7: e44687.
23. Chung SD, Kuo YC, Kuo HC (2012) Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome. Pain Physician 15: 1972202.
24. Nickel JC, Barkin J, Forrest J, Mosbaugh PG, Hernandez-Graulau J, et al. (2005) Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology 65: 6542658.
25. Vizzard MA (2000) Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp Neurol 161: 2732284.
26. Iavazzo C, Athanasiou S, Pitsouni E, Falagas ME (2007) Hyaluronic acid: an effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis? Eur Urol 51: 153421540; discussion 154021531.
27. Steers WD, Tuttle JB (2006) Mechanisms of Disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol 3: 1012 110.
28. Pezet S, Malcangio M, McMahon SB (2002) BDNF: a neuromodulator in nociceptive pathways? Brain Res Brain Res Rev 40: 2402249.
29. Pinto R, Frias B, Allen S, Dawbarn D, McMahon SB, et al. (2010) Sequestration of brain derived nerve factor by intravenous delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals with chronic cystitis. Neuroscience 166: 9072916.
30. Liu HT, Tyagi P, Chancellor MB, Kuo HC (2009) Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int 104: 147621481.
31. Pinto R, Lopes T, Frias B, Silva A, Silva JA, et al. (2010) Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 58: 3602365.
32. Ho DR, Chen CS, Lin WY, Chang PJ, Huang YC (2011) Effect of hyaluronic acid on urine nerve growth factor in cyclophosphamide-induced cystitis. Int J Urol 18: 5252531.
33. Lai MC, Kuo YC, Kuo HC (2013) Intravesical hyaluronic acid for interstitial cystitis/painful bladder syndrome: a comparative randomized assessment of different regimens. Int J Urol 20: 2032207.